ArticleThe Journal of antimicrobial chemotherapy2026
A fluorogenic biotracer for reliable detection of staphylococcal beta-lactamase: towards improved precision therapy in severe MSSA infections.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesAccurate detection of staphylococcal beta-lactamase remains a diagnostic challenge, despite its importance for guiding antibiotic therapy, particularly in severe infections, such as endocarditis and bacteraemia. Currently, no available method reliably detects beta-lactamase activity in all staphylococcal species. Here, we evaluated a novel fluorogenic biotracer, 352600-C (MOLSID, Lyon, France), designed to detect beta-lactamase activity in staphylococci.
methodsThe 352600-C biotracer was incorporated into Mueller-Hinton agar plates onto which staphylococcal strains were subcultured at 37°C. Colony fluorescence was assessed at 4, 6 and 24 h using a 365 nm UV lamp. The assay was performed on a large collection of blaZ-positive (n = 124, including BlaZ types A, B, C and D) and blaZ-negative (n = 69) staphylococci from 18 species (Staphylococcus aureus, n = 100; S. non-aureus, n = 93). Molecular detection of the blaZ gene using WGS served as the gold standard. Phenotypic susceptibility to penicillins was also tested using EUCAST recommendations.
resultsAfter 4, 6 and 24 h of incubation, the assay showed sensitivities of 92.2%, 96.9% and 100% for S. aureus and 50.0%, 88.3% and 100% for non-aureus staphylococci, respectively. None of the 69 blaZ-negative strains produced fluorescent colonies (specificity 100%). Notably, the assay detected all BlaZ types. Penicillin disc diffusion showed 98.4% sensitivity and 77.8% specificity for MSSA.
conclusionsThis novel assay for the detection of staphylococcal beta-lactamase demonstrated simplicity, rapidity and excellent accuracy after 24 h incubation (100% sensitivity and specificity) across a genetically diverse and representative collection of clinical isolates, making it a valuable tool for routine diagnostics and antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.